Analysis of the CYP2C19 genetic polymorphism in Han and Uyghur patients with cardiovascular and cerebrovascular diseases in the Kashi area of Xinjiang.
BACKGROUND
The aim of this study was to analyze the CYP2C19 genetic polymorphism among Han and Uyghur patients with cardiovascular and cerebrovascular diseases in the Kashi area of Xinjiang.


METHODS
We enrolled 1020 patients with cardiovascular and cerebrovascular diseases, including 220 Han subjects and 800 Uyghur subjects. We used the gene chip method to detect polymorphisms in CYP2C19. The allele frequencies of CYP2C19 and the metabolic phenotype frequencies were then compared between the 2 ethnic groups.


RESULTS
The frequency of CYP2C19 *1 was 0.6454 in Han subjects and 0.7869 in Uyghur subjects, and the difference was statistically significant (P<0.05). The frequency of CYP2C19 *2 was 0.3273 in Han subjects and 0.1837 in Uyghur subjects (P<0.05). The frequency of the homozygous extensive metabolizer phenotype was 42.72% and 62.13% in Han and Uyghur subjects, respectively (P<0.01). The frequency of the heterozygous extensive metabolizer phenotype was 43.64% and 33.13% in Han and Uyghur subjects, respectively (P<0.01). The frequency of poor metabolizers in Han and Uyghur subjects was 13.64% and 4.76%, respectively (P<0.01).


CONCLUSIONS
Among patients with cardiovascular and cerebrovascular diseases located in the Kashgar Prefecture of Xinjiang, there is a differential distribution of CYP2C19 genotypes between the Han and Uyghur populations. Uyghur patients showed higher frequencies of extensive metabolizer genotypes than Han patients, while Han patients showed higher frequencies of poor metabolizer genotypes than Uyghur patients.
Clinical laboratory, First People's Hospital of Xinjiang Kashi Area, Kashi, Xinjiang, China (mainland).
Yadong
Y
Li
Department of Cardiology, First People's Hospital of Xinjiang Kashi Area, Kashi, Xinjiang, China (mainland).
Heyin
H
Yang
Department of Pharmacy, First People's Hospital of Xinjiang Kashi Area, Kashi, Xinjiang, China (mainland).
Xiaoguang
X
Zou
Department of Science and Education, First People's Hospital of Xinjiang Kashi Area, Kashi, Xinjiang, China (mainland).
Lijun
L
Xiong
Medical College of Shi Hezi University, Xinjiang Uighur Autonomous Region, Shihezi, Xinjiang, China (mainland).
Zhen
Z
Li
Department of Science and Education, First People's Hospital of Xinjiang Kashi Area, Kashi, Xinjiang, China (mainland).
Jianzhang
J
Luo
Department of Pharmacy, First People's Hospital of Xinjiang Kashi Area, Kashi, Xinjiang, China (mainland).
Bo
B
Zhao
Clinical Laboratory, First People's Hospital of Xinjiang Kashi Area, Kashi, Xinjiang, China (mainland).
Wen
W
Liu
Clinical laboratory, First People's Hospital of Xinjiang Kashi Area, Kashi, Xinjiang, China (mainland).
Xili
X
Du
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D044466:Asian People / Q000235:genetics*; D002318:Cardiovascular Diseases / Q000235:genetics; D002561:Cerebrovascular Disorders / Q000235:genetics*; D002681:China; D065731:Cytochrome P-450 CYP2C19 / Q000235:genetics* / Q000378:metabolism; D005006:Ethnicity / Q000235:genetics*; D005787:Gene Frequency; D020022:Genetic Predisposition to Disease; D006801:Humans; D008875:Middle Aged; D009154:Mutation / Q000235:genetics; D010641:Phenotype; D011110:Polymorphism, Genetic; D055815:Young Adult
D065731:Cytochrome P-450 CYP2C19